James David Brandt, M.D.
- Vice-Chair for International Programs & New Technology
- Director of the Glaucoma Service
- Professor of Ophthalmology & Vision Science
Dr. Brandt’s clinical practice is limited to the diagnosis and management of all forms of glaucoma, with a particular focus on infantile and pediatric glaucoma.
He participates (and offers his patients the opportunity to be involved in) clinical trials of new medical and surgical approaches to the treatment of glaucoma.
Dr. Brandt is a frequent volunteer faculty member with ORBIS International, traveling worldwide to train glaucoma specialists in the management of pediatric glaucoma.
Dr. Brandt has research interests in both the clinical and basic realms. In clinical research, he is a principal investigator in the landmark Ocular Hypertension Treatment Study and was largely responsible for one of the Study's most important findings to date, that thin corneal thickness is a risk factor for the development of glaucoma.
Dr. Brandt is actively involved in large clinical trials investigating new medical and surgical treatments of glaucoma and new technologies for diagnosing the disease. In the basic research arena, Dr. Brandt is currently collaborating with Dr. Tingrui Pan of the Department of Biomedical Engineering to develop new MEMS and Nanotechnology-based devices for the diagnosis of glaucoma.
M.D., Harvard Medical School, Boston MA 1982
B.S., Yale University, New Haven CT 1978
Ophthalmology, University of Southern California, Los Angeles CA 1985-1988
Opthalmalmic Pharmacology & Cell Biology, Harvard Medical School - Eye Research Institute, Boston MA 1983-1985
Glaucoma, Wills Eye Hospital, Philadelphia PA 1988-1989
American Board of Ophthalmology, 1989
American Academy of Ophthalmology
American Glaucoma Society
American Medical Association
Association for Research in Vision and Ophthalmology
California Association of Eye Physicians and Surgeon
California Medical Association
Glaucoma Research Society
World Glaucoma Association
Honors and Awards
Lifetime Achievement Award (American Academy of Ophthalmology, 2015
13th Annual Clinician-Scientist Lecturer (American Glaucoma Society, 2012
Listed in "Best Doctors in America" 1998-, 2016
Select Recent Publications
Nie B, Li R, Brandt JD & Pan T. Flexible transparent iontronic film for interfacial capacitive pressure sensing. Advanced Materials. 2015;27(39):6055-6062
Suhr AW, Lim MC, Brandt JD, Izquierdo JC & Willits N. Outcomes of Fornix-based versus Limbus-based Conjunctival Incisions for Glaucoma Drainage Device Implant. J of Glaucoma. 2012;21(8):523-529.
Gedde SJ, Schiffman JC, Feuer WJ, Herndon LW, Brandt JD, Budenz DL; Tube versus Trabeculectomy Study Group. Treatment outcomes in the Tube Versus Trabeculectomy (TVT) study after five years of follow-up. Am J Ophthalmol. 2012 May;153(5):789-803.
Brandt JD, Gordon MO, Gao F, Beiser JA, Miller JP & Kass MA. Ocular Hypertension Treatment Study Group Adjusting IOP for Central Corneal Thickness Does Not Improve Prediction Models for Primary Open-Angle Glaucoma. Ophthalmology. 2012;119(3):437-442.
Mochizuki H, Lesley AG & Brandt JD. Shrinkage of the scleral canal during cupping reversal in children. Ophthalmology. 2011;118(10):2008-2013.
Zangwill LM, Weinreb RN, Beiser J, Berry CC, Cioffi GA, Coleman AL, Trick G, Liebmann JM, Brandt JD, Piltz-Seymour JR, Dirkes KA, Vega S, Kass MA, Gordon MO. Ocular Hypertension Treatment CSLO Ancillary Study Group Predicting the Onset of Glaucoma: The Confocal Scanning Laser Ophthalmoscopy Ancillary Study to the Ocular Hypertension Treatment Study. Ophthalmology. 2010;117(9):1674-1683.
Brandt JD, Beiser JA, Gordon MO, Lin SC, Alexander MY, Kass MA. OHTS Study Group Changes in Central Corneal Thickness Over Time: The Ocular Hypertension Treatment Study. Ophthalmology. 2008;115(9):1550-1556.
Tanimoto SA & Brandt JD. Options in pediatric glaucoma after angle surgery has failed. Current Opinion in Ophthalmology. 2006;17:132-137.
Brandt, JD, Beiser JA, Gordon MO & Kass MA. Ocular Hypertension Treatment Study Group Central Corneal Thickness and IOP Response to Topical Ocular Hypotensive Medication in the Ocular Hypertension Treatment Study (OHTS). Am J of Ophthalmology. 2004;138(5):717-722.
Gordon MO, Beiser JA, Brandt JD, Heuer DK, Higginbotham EJ, Johnson CA, Keltner JL, Miller JP, Parrish RK, Wilson MR, Kass MA. Ocular Hypertension Treatment Study Group The Ocular Hypertension Treatment Study: Baseline Factors that Predict the Development of Primary Open Angle Glaucoma. Archives of Ophthalmology. 2002;120(6):714-720.